Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2547)	10/25/2018 4:30:00 PM
From: Miljenko Zuanic	Respond to of 3559

Model: hhs.gov <Here is how the model will work: Today’s system: Medicare sets payments for physician-administered drugs at the average sales price in the U.S. market—plus a price-based add-on fee.New model: Medicare sets the payment for these drugs at a Target Price, based on the discounts drug companies give other countries.With the model fully implemented, total payment for these drugs will drop by 30 percent.The Target Price is 126 percent of the average price other countries pay for the drug.The model incorporates a new, larger add-on fee for hospitals and doctors that is independent of prices.> So, what power REGN have to increase Eylea price in, for instance, Canada, in next few months?

To: Miljenko Zuanic who wrote (2547)	11/2/2018 3:54:18 AM
From: Miljenko Zuanic	Respond to of 3559

Again, to repeat here something that is EXTRA NON-ORDINARY for EYLEA: pmprb-cepmb.gc.ca * Eylea had less than 0.1% of the total pharmaceutical market share in the US, the lowest of all PMPRB7 countries.* In UK it is 5.1% or 51X times. For 2016 Medicare Part B , Eylea sale was $2.1B, and in UK was probably less than $400M (where price in UK is ~1/2 of US). Now, US NIH promoted compounding Avastin for AMD/DME (illegal action by government) and capture 65% volume share for AMD (somewhere less for DME), and inflict generic competition where should be none. Still, Trump used Eylea/Lucentis as example of non-competitive drug pricing. IF there is no compounding Avastin, 2016 PartB drug expenditure for Eylea + Lucentis would be ~$9B. There is already ~$6B saving/year from this ILLEGAL government practice. So, IF REGN/Roche is to take legal action against US government, (as they have right to protect their respective IP), as Novartis/Bayer are doing in EU,.....story would be completely different today.